Lupin: FIRST to win Canadian approval for generic version of Inderal-LA capsules
Lupin is the first generic company to receive approval for generic Inderal-LA capsules for the Canadian market and the product will be manufactured at the company's Pithampur unit-2 facility, it added.
New Delhi: Drug firm Lupin on Friday said it has received approval from the Canadian health regulator for its Propranolol Hydrochloride extended-release capsules used for the treatment of hypertension and decrease the frequency of angina.
The company has received approval for its Propranolol Hydrochloride extended-release (ER) capsules in the strengths of 60 mg, 80 mg, 120 mg and 160 mg from Health Canada, Lupin said in a statement.
The company's product is the generic version of Pfizer Canada ULC's Inderal-LA capsules in the same strengths, Lupin said.
As per IQVIA MAT December 2018 data, Propranolol Hydrochloride ER capsules had an annual sales of approximately CAD 8.6 million in the Canadian market, it added.
The capsules are indicated in the treatment of hypertension and for the prophylaxis of angina pectoris, Lupin said.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd